<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04880343</url>
  </required_header>
  <id_info>
    <org_study_id>FJD-URO-19-001</org_study_id>
    <nct_id>NCT04880343</nct_id>
  </id_info>
  <brief_title>Clinical Study to Evaluate the Efficacy of the Dietary Supplement UROMANNOSA® in Women With Recurrent Lower Urinary Tract Infections</brief_title>
  <official_title>Randomised, Open-label, Controlled Clinical Trial to Evaluate the Efficacy of a Product Consisting of D Mannose 2 g+ Cran-max 500 mg+ Vitamin D3 0.001 mg (UROMANNOSA®) in Women With Recurrent Lower Urinary Tract Infections</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Carmen Gonzalez Enguita</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To analyze the clinical impact of a food supplement composed of D Mannose, cranberry extract&#xD;
      (Cran-max) and Vitamin D3 in the prevention of recurrent lower urinary tract infections (UTI)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Once patients have been informed about the study, the potential risks and treatment&#xD;
      alternatives, those who meet the selection criteria, agree to participate and sign the&#xD;
      informed consent, will be randomly and openly assigned, in a 1:1:1 ratio, to one of the&#xD;
      following groups:&#xD;
&#xD;
      Group A: Patients with repeat UTIs who will receive prophylactic treatment for 6 Months.&#xD;
&#xD;
      Group B: Patients with repeat UTIs who will receive prophylactic treatment for 3 Months.&#xD;
&#xD;
      Control group: Patients with recurrent UTIs who will not receive as prophylactic treatment&#xD;
      the supplement under study.&#xD;
&#xD;
      The three groups will be treated following standard clinical practice with follow-up at 3, 6,&#xD;
      9 and 12 months after inclusion.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 26, 2021</start_date>
  <completion_date type="Anticipated">January 26, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 26, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>UTI Recurrence</measure>
    <time_frame>Through study completion, an average of one year</time_frame>
    <description>Number of patients with recurrences (defined as: number of patients with at least one UTI during the study period) at 6 months.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>UTI Recurrence</measure>
    <time_frame>Variable for each participant over course of up to one year</time_frame>
    <description>Time (in days) from the start of treatment to the next episode of UTI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of symptomatic UTIs</measure>
    <time_frame>Variable for each participant over course of up to one year</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Lower Urinary Tract Infection</condition>
  <arm_group>
    <arm_group_label>Group (C)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Control</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group (A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group (B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Group (A)</intervention_name>
    <description>Group that will take a daily dose of the commercial dietary supplement provided by the sponsor, composed of mannose, cran-max and vitamin D for 6 months</description>
    <arm_group_label>Group (A)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Group (B)</intervention_name>
    <description>Group that will take a daily dose of the commercial dietary supplement provided by the sponsor, composed of mannose, cran-max and vitamin D for 3 months</description>
    <arm_group_label>Group (B)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  History of Recurrent Lower Urinary Tract Infection (at least two episodes in the last&#xD;
             6 months or three episodes in the last 12 months).&#xD;
&#xD;
          -  Multiple infections must be spaced a minimum of 2 weeks apart or if less, with a&#xD;
             negative urine culture in between.&#xD;
&#xD;
          -  Women who agree to participate and give their informed consent in writing&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of antibiotics or cranberry or other preventive treatment, pharmacological or not,&#xD;
             for recurrence of urinary tract infections in the last two weeks.&#xD;
&#xD;
          -  Patient with indwelling catheter or intermittent catheterization.&#xD;
&#xD;
          -  Patients who present: Interstitial Cystitis, Neurogenic Bladder, Diabetes Mellitus,&#xD;
             Nephrolithiasis, Cervical-Uterine Cancer diagnosed and treated less than 5 years ago.&#xD;
&#xD;
          -  Use of anticoagulants or contraceptive methods using spermicides or diaphragms.&#xD;
&#xD;
          -  Women consuming probiotics or foods, beverages or supplements containing extracts or&#xD;
             parts of the genus Vaccinum sp, including other forms of V. macrocarpon (blueberry),&#xD;
             V. myrtillus (European blueberry), V.angustifolium (wild or lowbush blueberry), V.&#xD;
             corymbosum ( highbush blueberry) or V. vitis-ideae (mountain blueberry), during the&#xD;
             two weeks prior to recruitment.&#xD;
&#xD;
          -  High consumption of fruits rich in phenolic compounds, with special reference to&#xD;
             berries.&#xD;
&#xD;
        Women allergic to berries&#xD;
&#xD;
          -  Pregnant or breastfeeding women.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Not based on self-representation</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Carmen González Enguita, PhD, Dr</last_name>
    <phone>+34915504800</phone>
    <phone_ext>31111</phone_ext>
    <email>cgenguita@fjd.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maria Garranzo, PhD</last_name>
    <phone>+34615369451</phone>
    <email>maria.garranzo@quironsalud.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitario Fundación Jiménez Díaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmen Gonzalez Enguita, PhD, Dr.</last_name>
      <phone>+34915504800</phone>
      <phone_ext>3111</phone_ext>
      <email>cgenguita@fjd.es</email>
    </contact>
    <contact_backup>
      <last_name>Maria Garranzo, PhD</last_name>
      <phone>+34915504800</phone>
      <phone_ext>3111</phone_ext>
      <email>maria.garranzo@quironsalud.es</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 29, 2021</study_first_submitted>
  <study_first_submitted_qc>May 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 10, 2021</study_first_posted>
  <last_update_submitted>May 5, 2021</last_update_submitted>
  <last_update_submitted_qc>May 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz</investigator_affiliation>
    <investigator_full_name>Carmen Gonzalez Enguita</investigator_full_name>
    <investigator_title>Staff Physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Urinary Tract Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

